211 results about "Abnormal expression" patented technology

The present invention discloses a nucleic acid aptamer binding to CD117 protein and its application, wherein the nucleic acid aptamer has a nucleotide sequence that has at least 60% homology with any one of SEQ ID NO.1 to SEQ ID NO.2 and binds to CD117 protein. The nucleic acid aptamer of the present invention has a small molecular weight, stable structure and chemical properties, is easy to store and label, is easy to modify, and can be artificially synthesized in a short period of time. The nucleic acid aptamer obtained by the present invention can be used for CD117 protein detection, purification or imaging, and can also be used to prepare drugs for diagnosis or treatment of abnormal expression of CD117 protein, such as purification to obtain high-sensitivity and high-specificity detection of CD117 protein, and has broad application prospects.

The invention discloses an application of an RhRAP2.4 gene in regulation of axillary bud germination of Chinese rose. Relates to the technical field of biology, and provides application of a product for inhibiting expression of an RhRAP2.4 gene or transcriptional translation protein of the RhRAP2.4 gene in promoting germination of rosa chinensis axillary buds, and the nucleotide sequence of the RhRAP2.4 gene is shown as SEQ ID NO.1. According to expression results of the RhRAP2.4 in different site buds of rosa chinensis branches, the RhRAP2.4 in the axillary buds is instantaneously silenced, and the rosa chinensis axillary bud germination is promoted. It is found that abnormal expression of the RhRAP2.4 can influence germination and growth of the axillary buds, silent RhRAP2.4 can inhibit growth of the axillary buds, and overexpressed RhRAP2.4 can promote growth of the axillary buds.

The invention relates to the technical field of spermidine application, in particular to application of spermidine in preparation of medicine for preventing and treating doxorubicin-induced cardiotoxicity and myocardial aging. Cell proliferation experiments and mouse survival rate experiments show that spermidine can reduce death of myocardial cells and mice caused by adriamycin; a q-PCR experiment shows that spermidine can improve abnormal expression conditions of P53, P21, P16, BAX, TNF-alpha, IFN alpha, IL-10 and IL-18 in myocardial cells caused by adriamycin; a beta-galactosidase staining experiment shows that the spermidine can reduce the condition that the expression of a marker beta-galactosidase for myocardial cell senescence induced by adriamycin is increased; a Western Blot experiment shows that the spermidine can improve the condition that the P53 protein is abnormally increased due to the adriamycin; an Elisa experiment shows that spermidine can improve the condition that myocardial injury markers cTn-I and AST and inflammatory factors IL-1beta are abnormally increased due to adriamycin, and the myocardial injury markers cTn-I and AST and inflammatory factors IL-1beta are abnormally increased due to adriamycin. Therefore, spermidine can improve cardiotoxicity and myocardial aging induced by adriamycin.

Disclosed are compounds having PTPN2 inhibitory effects and a use thereof. Specifically, disclosed are a class of compounds having protein tyrosine phosphatase inhibitory effects or pharmaceutically acceptable salts thereof, as well as a use thereof for treating and / or preventing diseases or conditions related to abnormal expression of protein tyrosine phosphatase. The compounds are represented by formula (I).

The invention discloses a kit and method for detecting leukemia and lymphoma based on full-spectrum flow cytometry, the kit comprises 25 antibodies, the antibodies are specifically bound with fluorescein respectively, and leukemia and lymphoma are detected through full-spectrum flow cytometry; the 25 kinds of antibodies comprise HLA-DR (human leukocyte antigen-DR), CD38, CD7, CD34, Lambda, CD19, CD64, CD14, CD5, CD123, CD16, CD20, Kappa, CD117, CD13, CD45, CD11b, CD2, CD10, CD8, CD15, CD4, CD3, CD56 and CD33. The kit comprehensively covers development stages of various lines of bone marrow cells, and common abnormal expressions of various leukemia, myelodysplastic syndromes and lymphoma, and can preliminarily screen various leukemia and lymphoma.

The invention relates to an anti-CK18 monoclonal antibody or an antigen binding fragment thereof, a detection reagent based on the anti-CK18 monoclonal antibody, and a preparation method and application of the anti-CK18 monoclonal antibody or the antigen binding fragment. According to the present invention, the anti-CK18 monoclonal antibody or the antigen binding fragment thereof can specifically bind with the CK18 protein or the fragment thereof with the high affinity, such that the low detection lower limit and the high detection sensitivity can be provided when the anti-CK18 monoclonal antibody or the antigen binding fragment thereof is used for the immunological detection of CK18; therefore, the monoclonal antibody or the antigen binding fragment of the monoclonal antibody has extremely high potential to be developed into an immunodetection antibody or a kit of the CK18 protein, or a diagnostic antibody or a diagnostic kit of diseases (such as NASH) related to abnormality of the CK18 protein (such as abnormal expression level), and has relatively great clinical application prospect and value.

The invention provides an NSD protein degradation agent and application thereof, and particularly provides a compound with a structure as shown in a formula (I) or pharmaceutically acceptable salt thereof, or a stereoisomer or a prodrug molecule thereof. The compound can degrade proteins such as NSD2, NSD1, NSD3, c-MYC, KLK3 / PSA, AR, NKX3.1, GSPT1 and the like in a targeted ubiquitination manner, so that the compound can be used for treating indications related to abnormal expression of the proteins such as NSD2, NSD1, NSD3, c-MYC, KLK3 / PSA, AR, NKX3.1, GSPT1 and the like. # imgabs0 #

The invention relates to the field of biotechnology and cell therapy, in particular to a recombinant construct, a CAR (chimeric antigen receptor) modified cell and application. On the objective basis of different antigen target spots, such as CD19, CLDN18.2 or BCMA and other different antigen target spots corresponding to abnormal expression of tumors, the target spots are used as target spots for clinical treatment; under the condition that the expression of the chimeric antigen is not changed, two cell factors are secreted synergistically; the long-term treatment effect of immune cells is enhanced, and meanwhile, the treatment risk is reduced.

The invention provides application of a sperm tRNA (transfer ribonucleic acid) derived fragment 5 'tRF-Glu-CTC in prediction of development potential of assisted reproductive embryos. The expression of a tRNA derived fragment 5 'tRF-Glu-CTC in a sperm sample is detected, the abnormal expression of the sperm specific tRNA derived fragment 5' tRF-Glu-CTC in a DFI increase patient is verified, and the analysis on the correlation with clinical data and reproductive outcome of the patient prompts that the 5 'tRF-Glu-CTC molecular marker has significant correlation with the reproductive outcome, so that the 5' tRF-Glu-CTC molecular marker can be used for detecting the expression of the sperm specific tRNA derived fragment 5 'tRF-Glu-CTC in the DFI increase patient. The embryonic development potential can be effectively predicted, and a biomarker is provided for assisted reproduction treatment. In different experimental groups, the 5 'tRF-Glu-CTC can significantly improve the prediction precision, and shows good prediction performance in different clinical data. The detection method based on the fragment is expected to become a new tool for evaluating the assisted reproduction curative effect, the reproduction treatment scheme is further optimized, and the success rate is improved.

The invention discloses a dual-recognition-framework nucleic acid probe, a preparation method and application, the dual-recognition-framework nucleic acid probe comprises a DNA tetrahedron, and a dual-recognition module and a fuel amplification module which are connected to the vertex of the DNA tetrahedron through complementary pairing of bases, ATP recognition protection and dual-target response are introduced, and the dual-recognition-framework nucleic acid probe is obtained through sequential opening of internal and external locks. The occurrence of false positive conditions can be reduced, and the specificity is effectively improved; signal amplification is realized by virtue of abnormal APE1 expression of tumor cells, so that a fluorescence signal for miRNA detection is increased, and the sensitivity and the imaging signal-to-noise ratio are effectively improved; the preparation is easy; the use is convenient; complicated equipment is not needed. The method can be applied to a target nucleic acid detection reagent or an imaging or positioning reagent of cells, tissues or organs containing target nucleic acid.

The invention discloses an antibody combination and a system for detecting leukemia stem cells. The antibody combination comprises a CD7 antibody, a CD371 antibody, a CD34 antibody, a CD45RA antibody, a CD123 antibody, a CD133 antibody, a CD38 antibody, a CD45 antibody, a CD90 antibody, a CD33 antibody and a CD19 antibody. The antibody combination provided by the invention can accurately identify target cells and distinguish normal HSCs and pluripotent progenitor cells in a CD34 + CD38-cell population, and the specific antibody has abnormal expression or expression intensity change, so that leukemia stem cells can be rapidly, simply and conveniently detected with high accuracy, high sensitivity and high specificity, the sensitivity of MRD evaluation is favorably improved, and the kit has a good application prospect. Therefore, signs of disease recurrence can be found earlier, more information about disease prognosis can be provided, and doctors and patients can be helped to better understand disease prognosis and possible results.

Provided are antibodies that include amino acid sequences of SEQ ID NOs: 2, 4, and 6-12, or amino acid sequences that are about 95% identical thereto, and fragments thereof. Also provided are scFv peptides that include a VH segment having a first amino acid sequence of amino acids 4-113 of any one of SEQ ID NOs: 2 and 8-12, a VL segment having a second amino acid sequence having amino acids 113-237 of SEQ ID NOs. 2 and 8-12, or both; nucleic acids encoding the same; methods for using the same to detect and / or target conformational states of FN in samples; methods for treating diseases and / or disorders and / or for meliorating at least one symptom of consequence of a disease or disorder associated with abnormal expression of a force-induced conformational state of FN in subjects; and methods for screening for compounds having selective binding activities for conformational states of FN.

The present invention provides an NSD protein degradation agent and a use thereof. Specifically, the present invention provides a compound having a structure as shown in formula (I) or a pharmaceutically acceptable salt thereof, or a stereoisomer or prodrug molecule thereof. The compound can degrade proteins such as NSD2, NSD1, NSD3, c-MYC, KLK3 / PSA, AR, NKX3.1, and GSPT1 via target ubiquitination, and therefore can be used to treat indications related to abnormal expression of proteins such as NSD2, NSD1, NSD3, c-MYC, KLK3 / PSA, AR, NKX3.1, and GSPT1.

Colorectal cancer (CRC) has not benefited from innovative immunotherapies, mainly because of the lack of actionable immune targets. Novel tumor-specific antigens (TSAs) and tumor-associated antigens (TAAs) expressed by CRC cells are described herein. Most of the TSAs described herein derives from aberrantly expressed unmutated genomic sequences, such as intronic and intergenic sequences, which are not expressed in normal tissues. Nucleic acids, compositions, cells, antibodies and vaccines derived from these TSAs are described. The use of the TSAs, nucleic acids, compositions, antibodies, cells and vaccines for the treatment of CRC is also described.

The present application discloses a method of determining suitability of treating a patient suffering from cancer or metastasis of cancer characterized by aberrant expression of MUC1, with a MUC1* targeting therapeutic.

The present application discloses a method of determining suitability of treating a patient suffering from cancer or metastasis of cancer characterized by aberrant expression of MUC1, with a MUC1* targeting therapeutic.

The invention relates to the technical field of biological medicines, and discloses a blocking antibody targeting CXCL6 and an application of the blocking antibody in preparation of antitumor drugs. The antibody or antigen-binding fragment thereof is capable of binding specifically to human CXCL6 protein with high affinity (e.g., Kd < = 1 nM). According to the invention, the specificity and high affinity of the antibody are verified by Western Blot, immunofluorescence, immunohistochemistry and surface plasmon resonance (SPR) technologies. Functional experiments show that the antibody can effectively block CXCL6-induced neutrophil chemotaxis, including in Transwell, a three-dimensional gel model and a zebra fish living body model. Besides, in a mouse MC38 colon cancer model, the antibody shows remarkable anti-tumor activity and can inhibit tumor growth driven by CXCL6. The invention also provides a pharmaceutical composition containing the antibody, and application of the antibody in preparation of drugs for preventing or treating diseases (such as inflammatory diseases, autoimmune diseases and cancers) related to abnormal expression or activity of CXCL6.

The invention belongs to the technical field of bioactive peptides, and particularly relates to a phycocyanin peptide and application thereof in preparation of a product with functions of inhibiting PTGS2 expression and regulating an Akt / GSK3beta signal channel. According to the invention, phycocyanin is taken as a raw material, active polypeptides with specific sequences are obtained through an enzymolysis separation technology, and the amino acid sequences of the active polypeptides are respectively Leuu-Ala-Ser and Leuu-Gly-Leu. Experiments prove that the phycocyanin peptide prepared by the invention can significantly inhibit the expression of PTGS2, and can play a related regulation role by activating an Akt / GSK3beta signal channel, so that the technical blank of plant active peptide targeting PTGS2 and Akt / GSK3beta signal channels is filled, and the phycocyanin peptide can be widely applied to the development of related products for regulating the abnormal expression of PTGS2 and Akt / GSK3beta signal channels.

The application provides a personalized cancer driver gene identification method based on network propagation, and the implementation steps are as follows: obtaining related data of cancer driver gene identification; performing data fusion on abnormal genomics data; constructing a cancer gene regulation network of a group; constructing a personalized cancer gene regulation network; calculating influence score of a node pair; and obtaining a personalized cancer driver gene identification result through a network propagation process. In the process of constructing the personalized cancer gene regulation network, statistical analysis is performed on the interaction between each pair of genes of each patient, so that the deviation of the network model caused by abnormal expression of a single gene in the prior art is avoided; and in the process of network propagation, various genomics data and topological information in the network are integrated, the information abundance in the network model is improved, and the accuracy of identifying personalized driver genes is effectively improved.

The invention provides an application of a pair of immune costimulatory factors TNFSF9 / TNFRSF9 as markers in preparation of a product for early prediction of preeclampsia, and the immune costimulatory factors comprise a tumor necrosis factor superfamily member 9 (TNFSF9) and a tumor necrosis factor receptor superfamily member 9 (TNFRSF9). The product is used for carrying out early warning on the preeclampsia occurrence risk 20 weeks before pregnancy. The product is used for detecting the immune costimulatory factor through at least one of serum, plasma, whole blood and placental tissue. The invention aims to improve the early prediction efficiency of preeclampsia by detecting the abnormal expression level of the pair of markers.

The present disclosure relates to a nucleoside analogue and a use thereof. The nucleoside analogue is a compound shown in formula (Ia) or a prodrug thereof. The nucleoside analogue can enhance targeted delivery of oligonucleotide drugs to nervous system cells, thereby increasing the inhibition rate of the oligonucleotide drugs delivered in a targeted manner on expression of specific genes in the nervous system cells, or enabling the oligonucleotide drugs delivered in a targeted manner to achieve the purpose of preventing and / or treating pathological conditions or diseases caused by abnormal expression of the specific genes in the nervous system cells. The present disclosure also relates to a nucleotide analogue-containing double-stranded oligonucleotide and a use thereof. The double-stranded oligonucleotide comprises a sense strand and an antisense strand, each strand has 17-25 modified and / or unmodified nucleotides, and the antisense strand and the sense strand are complementary to form a duplex region; the sense strand and / or the antisense strand contains at least one nucleotide analogue represented by the structure of formula (100), or a tautomer, or stereoisomer, or pharmaceutically acceptable salt thereof; the double-stranded oligonucleotide can effectively treat and / or prevent pathological conditions or diseases caused by abnormal expression of specific genes in nervous system cells.

Provided are an antibody targeting Trop2, an antibody-drug conjugate, and use thereof. The provided antibody targeting Trop2 is capable of specifically binding to a target cell expressing human Trop2, has high affinity with same, is capable of entering the cell by means of endocytosis and inhibiting tumor growth or progression, and can be used for treating, preventing, and ameliorating conditions in a subject associated with abnormal expression of Trop2 (e.g., breast cancer, urothelial carcinoma, and non-small cell lung cancer).

The present invention provides a bioluminescence probe for detecting norepinephrine, its preparation method and use, belonging to the field of biological detection. The bioluminescence probe of the present invention has high selectivity and high responsiveness to norepinephrine, can specifically recognize norepinephrine, has high sensitivity and low detection limit, and can be used for the precise detection of norepinephrine. In the range of pH 1.0 to 7.4, the bioluminescence probe of the present invention has excellent stability and can meet the application requirements under different physiological environments in vivo. At the same time, the norepinephrine bioluminescence probe of the present invention can also visually track exogenous norepinephrine at the in vivo level, and perform dynamic visual analysis on patients with diseases related to abnormal expression of norepinephrine involving nerves, tumors, blood pressure and heart diseases, which is beneficial to the clinical detection of norepinephrine and has broad application prospects.

The invention relates to the field of detection, in particular to a detection method of an exosome marker combination for monitoring postoperative recurrence of esophageal cancer. The method comprises the following steps: extracting exosomes from a serum sample of a patient, measuring expression levels of biomarkers related to recurrence of esophageal cancer in different exosome subgroups as original signal values, and selecting representative signal values from the original signal values; and performing standardization processing on the representative signal value, calculating a recurrence probability based on the standardized representative signal value of the biomarker, and performing risk classification. The problems that in a traditional exosome marker detection method, an average value or single subgroup data is generally directly taken as a representative signal, and abnormal expression characteristics cannot be highlighted; generally, the recurrence risk is predicted directly based on the expression level of a single time point, and the dynamic change trend of recent signals may be ignored. The technical problems of lack of comprehensive evaluation of the overall deviation trend of all markers and neglecting of the correlation between the distribution disorder degree and the recurrence risk in the prior art are generally solved.

The purpose of the present invention is to provide a compound, a method, and a pharmaceutical composition for normalizing dual homologous frame 4 (DUX4) in an individual in which the DUX4 gene is abnormally expressed, and to provide a modified oligonucleotide comprising 12-30 residues, comprising at least 8 contiguous nucleic acid base sequences, the modified oligonucleotide has a nucleic acid base sequence which is complementary to the isometric portion of the nucleic acid base of the mature mRNA of DUX4 of SEQ ID NO: 1 from the 5'terminal thereof at positions 126th to 147th, positions 232th to 248, positions 1306th to 1325th, or positions 1472nd to 1495th, and the nucleic acid base sequence of the modified oligonucleotide has at least 90% complementarity with the isometric portion of the nucleic acid base sequence of the mature mRNA of DUX4 of SEQ ID NO: 1.

The present disclosure provides a double-stranded oligonucleotide comprising a lipid-modified monomer and use thereof and pertains to the technical field of oligonucleotide drugs. In the present disclosure, a lipid group is introduced into a nucleotide monomer to prepare a modified nucleotide monomer, and the lipid-modified nucleotide monomer is utilized to prepare a double-stranded oligonucleotide, a double-stranded oligonucleotide conjugate, or a pharmaceutical composition. The modified double-stranded oligonucleotide, the double-stranded oligonucleotide conjugate, or the pharmaceutical composition can effectively treat and / or prevent pathological conditions or diseases caused by abnormal expression of a specific gene in target tissue-related cells.

Provided herein are compounds recognized as inhibitors of ADAR1 activity, such as compounds having the following formula (I) or (II), or pharmaceutically acceptable salts or tautomers thereof, which are useful in the treatment of cancer and other conditions, including those associated with aberrant ADAR1 expression.

The application provides an arginine methyltransferase 6 inhibitor and a preparation method, a pharmaceutical composition and a use thereof, relates to the technical field of biological medicine. The arginine methyltransferase 6 inhibitor provided by the application is a new compound obtained on the basis of a large number of design, synthesis and screening. The arginine methyltransferase 6 inhibitor is different from existing PRMTs inhibitors. The arginine methyltransferase 6 inhibitor can selectively degrade arginine methyltransferase 6, thereby regulating the protein level of arginine methyltransferase 6, has antitumor cell activity, can be used for preventing or treating diseases related to abnormal expression of PRMT6, and provides a new choice for development and application of antitumor drugs. The preparation method of the arginine methyltransferase 6 inhibitor provided by the application adopts raw materials which are easy to obtain, has the advantages of simple synthesis method, safety, easy realization and high yield, and can be used for industrial production.

The invention discloses a method for treating cancers by combined application of Mobosertinib and an anti-PD-1 antibody, researches on the synergistic effect of Mobosertinib on non-EGFR exon 20 insertion mutation diseases and the synergistic effect of Mobosertinib and the anti-PD-1 antibody, and finds that the action mechanism of Mobosertinib is related to abnormal expression of SET. The invention provides a technical scheme of new application and combined application of Mobosertinib, and a new research direction is provided for treatment of cancers related to SET abnormal expression.